The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering activity of one of the world’s leading life sciences companies.
On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.
The report will be delivered in PDF format within 1 working day of receipt of order. If the CD-Rom version purchased, the report will be sent by courier using express service.
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives.
The initial chapters of this report provide an orientation of deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top companies partnering with the company since 2010. Chapter 3 provides an overview of the leading partnering and M&A deals since 2010 to present date based on headline value.
Chapter 4 provides details on how to approach biopharma companies with partnering opportunities whilst chapter 5 lists forthcoming partnering events and conferences where biopharma companies will be present to discuss opportunities face to face.
The main body of the report is provided in chapter 6 providing a infographic visual summary of the company‘s partnering activity since 2010 according to deal type, industry sector, phase of development, and therapy area.
The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
Understanding the flexibility of prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
Each contract document is accessible through a link to an online version of the actual contract document as filed with the Securities Exchange Commission. Analyzing actual company agreements allows assessment of the following:
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o How is confidentiality and publication managed?
o How are disputes to be resolved?
o Under what conditions can the deal be terminated?
o What happens when there is a change of ownership?
o What sublicensing and sub-contracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Global Infectious Diseases Partnering 2014 to 2019 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Infectious Diseases partnering deals Financial deal terms for headline, upfront and royalty by stage of development Infectious...
501 pages •
By Roots Analysis Private Ltd.
• Mar 2019
INTRODUCTION Chronic disorders, such as diabetes, cancer, heart disease, obesity, and certain types of mental health problems, are considered among the leading causes of death and disability across the globe. According to a report published by the Center for Managing Chronic Disease at the University of Michigan in 2018,...
2019-2023 Competing in the Japan Cancer Diagnostics Market: Supplier Shares and Sales Segment Forecasts by Test, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities This new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market...
300 pages •
By Roots Analysis Private Ltd.
• Feb 2019
INTRODUCTION Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders. In the US, the annual economic burden associated with these disorders...
243 pages •
By Global Industry Analysts
• May 2019
This report analyzes the worldwide markets for Biosimilars in US$ Million. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary...
Global Biologics Market Research Report: by Product (Monoclonal Antibody, Interleukins, Vaccines, Growth Factors, Gene Therapy, Others), by Disease Indication (Rheumatoid Arthritis, Psoriasis/Psoriatic Arthritis, Cancer, Diabetes, Others), by Manufacturing (In-house, Sourced), and Region - Forecast to 2023 Market...
The Global Oncology Partnering 2014-2019: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Pipeline Review, H1 2019 Summary Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.